Table 1.
Baseline clinicopathological characteristics of HCC patients.
| Variables | No (%) | |
|---|---|---|
| Gender | Male | 77 (80.2) |
| Female | 19 (19.8) | |
| Viral etiology | HBsAg (+) | 66 (68.8) |
| Anti-HCV (+) | 25 (26.0) | |
| HBsAg (−), Anti-HCV (−) | 5 (5.2) | |
| Cirrhosis | With | 57 (59.4) |
| Without | 39 (40.6) | |
| Differentiation | Well | 24 (25.0) |
| Moderate | 49 (51.0) | |
| Poor | 23 (24.0) | |
| Tumor stage | I+II | 44 (45.8) |
| III+IV | 52 (54.2) | |
| Tumor number | Solitary | 72 (75.0) |
| Multiple | 24 (25.0) | |
| Capsule Intact | With | 57 (59.4) |
| Without | 39 (40.6) | |
| Tumor size (cm) | Mean (SD) | 6.50 ± 3.78 |
| Age (yrs) | Mean (SD) | 55.4 ± 12.2 |
| AFP(ng/ml) | Mean (SD) | 2883 ± 9429 |
| MVD | Mean (SD) | 109.5 ± 41.3 |
HBsAg: hepatitis B surface antigen, HCV: hepatitis C virus, MVD: microvessel density, AFP: alpha-fetoprotein.